Who are Atropine Sulfate 02's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atropine 1%, Atropine Sulfate 0.04% Eye Drop, Atropine sulfate eye drops 0.02%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atropine-sulfate-02.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Atropine Sulfate 02 — Competitive Intelligence Brief

Atropine Sulfate 02 (Atropine Sulfate 02) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent / Muscarinic receptor antagonist. Area: Emergency Medicine, Ophthalmology, Cardiology.

phase 3 Anticholinergic agent / Muscarinic receptor antagonist Muscarinic acetylcholine receptors (M1-M5) Emergency Medicine, Ophthalmology, Cardiology Small molecule Live · refreshed every 30 min

Target snapshot

Atropine Sulfate 02 (Atropine Sulfate 02) — LitePharmTech Co., Ltd.. Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Atropine Sulfate 02 TARGET	Atropine Sulfate 02	LitePharmTech Co., Ltd.	phase 3	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1-M5)
Atropine 1%	Atropine 1%	Massachusetts Eye and Ear Infirmary	marketed	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1-M5, primarily M3 in ocular tissue)
Atropine Sulfate 0.04% Eye Drop	Atropine Sulfate 0.04% Eye Drop	Shanghai Eye Disease Prevention and Treatment Center	marketed	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1, M3, M5)
Atropine sulfate eye drops 0.02%	Atropine sulfate eye drops 0.02%	Oupushifang Pharmaceutical Technology Co., Ltd.	phase 3	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1-M5, primarily M1 and M3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent / Muscarinic receptor antagonist class)

LitePharmTech Co., Ltd. · 1 drug in this class
Massachusetts Eye and Ear Infirmary · 1 drug in this class
Oupushifang Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Shanghai Eye Disease Prevention and Treatment Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atropine Sulfate 02 — Competitive Intelligence Brief. https://druglandscape.com/ci/atropine-sulfate-02. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab